

Notice of Introduction of New Prescription Drug Pursuant to 18 V.S.A. § 4637

Dear Office of the Attorney General:

Otsuka America Pharmaceutical, Inc. (“Otsuka”) is issuing this notice pursuant to 18 V.S.A. § 4637(b).

Otsuka has released Abilify Asimtufii into the market at a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.